Table 3. Pathways Differentially Modulated at TW4 Specifically in Patients Who Develop Depression (p⩽0.05).
| Pathway | Molecules |
|---|---|
| Aryl hydrocarbon receptor signaling | FOS, NCOR2, HSPB1, IL1B, ALDH1A1, NQO2, ALDH5A1, NFIA, MGST1, TFDP1, MGST3, NRIP1 |
| IL-6 signaling | FOS, A2M, HSPB1, IL1RN, IL1B, TNFAIP6, CD14, IL6R, AKT2, IL6ST |
| ERK5 signalinga | FOS, SGK1, GNA12, WNK1, GAB1, MAP3K3, IL6ST |
| Pentose phosphate pathwaya | TKT, PGD, TALDO1 |
| NRF2-mediated oxidative stress response | FOS, DNAJA4, DNAJC8, DNAJC6, GCLC, ABCC4, DNAJA2, DNAJC15, NQO2, MGST1, MGST3 |
| Phenylethylamine degradation Ia | ALDH2, AOC3 |
| NF-κB signaling | BMPR2, TNFSF13B, IL1RN, IL1B, AZI2, TLR6, PELI1, AKT2, MAP3K3, PLCG2 |
| LXR/RXR activation | NCOR2, S100A8, IL1RN, IL1B, MMP9, ORM1, CD14, PTGS2 |
| Ephrin B signaling | ACP1, EPHB4, GNAT2, GNA12, ROCK1, GNG2 |
| Production of nitric oxide and reactive oxygen species in macrophages | FOS, IFNGR1, NCF4, S100A8, ORM1, NCF1, SIRPA, AKT2, MAP3K3, PLCG2 |
| IL-8 signaling | FOS, MMP9, CXCR2, PTGS2, CXCR1, GNA12, ROCK1, BCL2L1, GNG2, AKT2 |
| Phosphatidylglycerol biosynthesis II (non-plastidic) | ABHD5, AGPAT9, PGS1 |
| GR signaling | KAT2B, NCOR2, IL1B, PPP3CA, AKT2, FOS, A2M, IL1RN, DUSP1, SGK1, PTGS2, BCL2L1, NRIP1 |
| Pentose phosphate pathway (non-oxidative branch)a | TKT, TALDO1 |
| Rapoport–Luebering glycolytic shunt | BPGM, MINPP1 |
| Glutathione redox reactions Ia | CLIC2, MGST1, MGST3 |
| Fatty acid alpha oxidation | ALDH1A1, PTGS2, ALDH2 |
| Pancreatic adenocarcinoma signalinga | NOTCH1, MMP9, PTGS2, E2F2, BCL2L1, TFDP1, AKT2 |
| RAR activation | FOS, KAT2B, NCOR2, RPL7A, PML, DUSP1, ALDH1A1, AKT2, NRIP1, PRKAR1A |
| Superpathway of inositol phosphate compounds | PPP1R8, DUSP1, PPTC7, ACP1, PPP4R1, SIRPA, PPP3CA, MINPP1, INPP5A, PLCG2 |
| Pyrimidine deoxyribonucleotides de novo biosynthesis I | AK5, NME4, RRM2B |
| Role of macrophages, fibroblasts and endothelial cells in rheumatoid arthritis | TNFSF13B, F2RL1, IL1B, IL6R, PPP3CA, AKT2, IL6ST, PLCG2, FOS, IL1RN, C5AR1, ROCK1, TLR6 |
| G beta gamma signaling | GNAT2, GNA12, GNG2, AKT2, PLCG2, PRKAR1A |
| Eicosanoid signaling | CYSLTR2, DPEP2, PTGS2, FPR2, TBXAS1 |
| Colorectal cancer metastasis signaling | FOS, IFNGR1, MMP9, PTGS2, IL6R, BCL2L1, TLR6, GNG2, AKT2, IL6ST, PRKAR1A |
| D-myo-inositol-5-phosphate metabolism | PPP1R8, DUSP1, PPTC7, ACP1, PPP4R1, SIRPA, PPP3CA, PLCG2 |
| Granulocyte adhesion and diapedesis | HSPB1, IL1RN, IL1B, MMP9, CXCL10, C5AR1, CXCR2, FPR2, HRH2 |
| Superpathway of D-myo-inositol (1,4,5)-trisphosphate metabolism | IMPA2, MINPP1, INPP5A |
| Prostanoid biosynthesis | PTGS2, TBXAS1 |
| PPAR signaling | FOS, NCOR2, IL1RN, IL1B, PTGS2, NRIP1 |
| EIF2 signalinga | RPL5, RPL7A, RPL13A, EIF4A1, RPL41, RPS2, AKT2, RPS15, AGO4 |
| p53 signaling | KAT2B, PML, BCL2L1, AKT2, RRM2B, PMAIP1 |
| Agranulocyte adhesion and diapedesis | IL1RN, IL1B, MMP9, CXCL10, C5AR1, CXCR2, CXCR1, AOC3, MYH9 |
| Toll-like receptor signaling | FOS, IL1RN, IL1B, CD14, TLR6 |
| Cholecystokinin/gastrin-mediated signaling | FOS, IL1RN, IL1B, PTGS2, GNA12, ROCK1 |
| D-myo-inositol (1,4,5,6)-tetrakisphosphate biosynthesis | PPP1R8, DUSP1, PPTC7, ACP1, PPP4R1, SIRPA, PPP3CA |
| D-myo-inositol (3,4,5,6)-tetrakisphosphate biosynthesis | PPP1R8, DUSP1, PPTC7, ACP1, PPP4R1, SIRPA, PPP3CA |
| Cardiac hypertrophy signaling | HSPB1, GNAT2, GNA12, IL6R, ROCK1, GNG2, PPP3CA, MAP3K3, PLCG2, PRKAR1A |
| Sorbitol degradation I | SORD |
| TREM1 signaling | NLRP12, IL1B, TLR6, AKT2, PLCG2 |
| Pyrimidine ribonucleotides interconversion | ENTPD1, AK5, NME4 |
| Axonal guidance signaling | MMP9, EPHB4, ADAM8, GNAT2, ARHGEF12, GNA12, TUBG1,PLXNC1, ADAM19, PPP3CA, AKT2, PLCG2, PRKAR1A, TUBA1A, ROCK1, GNG2 |
| HGF signaling | FOS, PTGS2, GAB1, AKT2, MAP3K3, PLCG2 |
| Molecular mechanisms of cancer | NOTCH1, GNAT2, ARHGEF12, GNA12, GAB1, AKT2, PRKAR1A, FOS, RALB, BMPR2, E2F2, BCL2L1, TFDP1, PMAIP1 |
| Relaxin signaling | FOS, MMP9, GNAT2, GNA12, GNG2, AKT2, PRKAR1A |
| Pyrimidine ribonucleotides de novo biosynthesis | ENTPD1, AK5, NME4 |
| Acute phase response signaling | FOS, A2M, IL1RN,I L1B, ORM1, IL6R, AKT2, IL6ST |
| Role of NFAT in regulation of the immune response | FOS, SYK, GNAT2, GNA12, GNG2, PPP3CA, AKT2, PLCG2 |
| Xenobiotic metabolism signaling | NCOR2, GCLC, IL1B, ALDH1A1, UGT2B7, NQO2, ALDH5A1, MGST1, MAP3K3, MGST3, NRIP1 |
| 3-Phosphoinositide degradation | PPP1R8, DUSP1, PPTC7, ACP1, PPP4R1, SIRPA, PPP3CA |
| Triacylglycerol biosynthesis | ABHD5, AGPAT9, LPPR2 |
| Communication between innate and adaptive immune cells | TNFSF13B, IL1RN, IL1B, CXCL10, TLR6 |
| Cardiolipin biosynthesis II | PGS1 |
| GM-CSF signaling | CSF2RA, BCL2L1, PPP3CA, AKT2 |
| G alpha i signaling | RALB, CXCR2, FPR2, P2RY14, GNG2, PRKAR1A |
| Aldosterone signaling in epithelial cells | HSPB1, DNAJC8, DNAJC6, DUSP1, SGK1, DNAJC15, PLCG2 |
| CDP-diacylglycerol biosynthesis I | ABHD5, AGPAT9 |
| Histamine degradation | ALDH1A1, ALDH2 |
| IL-1 signaling | FOS, GNAT2, GNA12, GNG2, PRKAR1A |
| RhoA signaling | LPAR6,ARHGEF12, GNA12, ROCK1, CDC42EP2, ARHGAP9 |
| Cell cycle: G1/S checkpoint regulation | RPL5, E2F2, NRG1, TFDP1 |
| Salvage pathways of pyrimidine ribonucleotides | SGK1, AK5, CDK8, NME4, AKT2 |
| Atherosclerosis signaling | S100A8, TNFRSF14, IL1RN, IL1B, MMP9, ORM1 |
| Docosahexaenoic acid (DHA) signaling | IL1B, BCL2L1, AKT2 |
| SAPK/JNK signalinga | MAP4K5, GNA12, GNG2, GAB1, MAP3K3 |
| Aryl hydrocarbon receptor signaling | FOS, NCOR2, HSPB1, IL1B, ALDH1A1, NQO2, ALDH5A1, NFIA, MGST1, TFDP1, MGST3, NRIP1 |
a
Pathways which were also modulated at TW24.